Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Article excerpt
BURLINGTON, N.C., Oct. 28, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH ), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year financial guidance. "Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance," said Adam Schechter, Chairman and CEO of Labcorp. "We furthered our leadership in specialty testing by launching innovative tests for advanced melanoma, Alzheimer's disease, and hepatitis D, while expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses. As healthcare continues to be transformed by advances in science and technology, personalized medicine, and evolving consumer expectations, Labcorp is well positioned to capitalize on these trends and drive sustainable long-term growth." Labcorp continues to advance its strategic priorities: Lead in specialty testing: Be the partner of choice for health systems and leading pharmaceutical companies: Collectively, these acquisitions and partnerships expand Labcorp's capabilities across specialty testing, clinical trials and women's health, strengthen customer relationships and enhance the company's ability to generate long-term growth...
Keep reading with a free account
The rest of this article, and every signal for Labcorp, is in your free account.
Extracted from this sentence
Net Earnings Attributable to Labcorp Holdings Inc. $ 262.8 $ 261.1 $ 839.3 $ 711.8
